CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway

Abstract

BackgroundAs a rapid‐progressing tumor, breast malignant phyllodes tumors (PTs) are challenged by the lack of effective therapeutic strategies and suitable prognostic markers. This study aimed to clarify the role and mechanism of CD146 on promoting PTs malignant progression, and to identify a novel prognosis marker and treatment target of breast malignant PTs.MethodsThe expression and prognostic significance of CD146 in PTs was detected through single‐cell RNA‐sequencing (scRNA‐seq), immunostaining, real‐time PCR and other methodologies. Functional experiments including proliferation assay, colony formation assay, transwell assay, and collagen contraction assay were conducted to validate the role of CD146 in malignant progression of PTs. The efficacy of anti‐CD146 monoclonal antibody AA98 against malignant PTs was corroborated by a malignant PT organoid model and a PT patient‐derived xenograft (PDX) model. Transcriptome sequencing, proteomic analysis, co‐immunoprecipitation, and pull‐down assay was employed to identify the modulating pathway and additional molecular mechanism.ResultsIn this study, the scRNA‐seq analysis of PTs disclosed a CD146‐positive characteristic in the α‐SMA+ fibroblast subset. Furthermore, a progressive elevation in the level of CD146 was observed with the malignant progression of PTs. More importantly, CD146 was found to serve as an independent predictor for recurrence in PT patients. Furthermore, CD146 was found to augment the viability and invasion of PTs. Mechanistically, CD146 acted as a protective “shield” to prevent the degradation of Discoidin, CUB, and LCCL domain‐containing protein 2 (DCBLD2), thereby activating the phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) signaling pathway and enhancing malignant behaviors of PT cells. In the malignant PT organoid and PDX model, a significant suppression of malignant PT growth was observed after the application of AA98.ConclusionsThese findings suggested that CD146 served as an efficacious marker for predicting PT malignant progression and showed promise as a prognosis marker and treatment target of breast malignant PTs. The study further unveiled the essential role of the CD146‐DCBLD2/PI3K/AKT axis in the malignant progression of PTs.